SOPHiA GENETICS CMO gets new options and RSUs
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported equity compensation grants consisting of options and restricted stock units tied to ordinary shares.
Rhea-AI Filing Summary
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported equity compensation grants consisting of options and restricted stock units tied to ordinary shares. He received a share option covering 164,671 ordinary shares at an exercise price of $5.04 per share, vesting 25% on April 2, 2027 and monthly through April 2, 2030. He also received 112,936 RSUs, each representing one ordinary share, vesting 25% on April 2, 2027 and the remaining 75% in equal quarterly installments through April 2, 2030, subject to continued service. Following these grants, his beneficial ownership of ordinary shares was corrected to 286,552 shares due to an earlier inadvertent reporting error.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 277,607 shares
Grant/Award
2 txns
Insider
Menu Philippe
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Share Option (Right to Buy) | 164,671 | $0.00 | $0.00 |
| Grant/Award | Ordinary Shares | 112,936 | $0.00 | $0.00 |
Holdings After Transaction:
Share Option (Right to Buy) — 164,671 contracts (Direct);
Ordinary Shares — 286,552 shares (Direct)
Footnotes (3)
- F1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
- F2. This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 112,936 ordinary shares due to an inadvertent error. The correct amount is 286,552 ordinary shares.
- F3. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Key Figures
Stock option grant: 164,671 options
Option exercise price: $5.04 per share
RSU grant size: 112,936 RSUs
+4 more
7 metrics
Stock option grant
164,671 options
Right to buy ordinary shares at $5.04 per share granted April 2, 2026
Option exercise price
$5.04 per share
Exercise price for 164,671-share option grant
RSU grant size
112,936 RSUs
Each RSU represents one ordinary share, granted April 2, 2026
Corrected share ownership
286,552 shares
Ordinary shares beneficially owned following transactions
RSU vesting start
April 2, 2027
25% of RSUs vest on this date, remainder quarterly to April 2, 2030
Option vesting start
April 2, 2027
25% of underlying shares vest, then monthly to April 2, 2030
Option expiration date
April 2, 2036
Expiration for the 164,671-share option grant
Key Terms
restricted stock unit ("RSU"), 2021 Equity Incentive Plan, vest, share option, +1 more
5 terms
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."
2021 Equity Incentive Plan financial
"RSU grant made under the Issuer's 2021 Equity Incentive Plan."
vest financial
"25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
beneficially owned financial
"correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction)."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How do the new RSUs for SOPH’s Chief Medical Officer vest?
The 112,936 RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. Each vested RSU entitles Philippe Menu to receive one ordinary share, provided he continues serving the company.
Why did SOPHiA GENETICS file an amended Form 4/A for SOPH?
The amended Form 4/A corrects the amount of ordinary shares beneficially owned after the reported transaction. A prior filing showed 112,936 shares due to an inadvertent error, while the correct post-transaction ownership is 286,552 ordinary shares held by Philippe Menu.
AI-generated analysis. How Rhea-AI works. Not financial advice.
